Page last updated: 2024-08-21

isoxazoles and Angiogenesis, Pathologic

isoxazoles has been researched along with Angiogenesis, Pathologic in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (35.29)29.6817
2010's11 (64.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belguise, K; Chen, B; Chen, L; Gao, J; Liu, C; Lu, K; Wang, X; Yi, B; Yu, W1
Balaraju, Y; Byrappa, S; Kotian, SY; Prabhuswamimath, SC; Rachaiah, K; Rai, KML; Salimath, BP1
Hamed, O; Kazem, A; Nasr, M; Selima, E1
Ainiwaer, A; Bao, Y; Cao, Q; Cheng, W; Mao, R; Wu, G; Xiao, L; Yang, Y1
Liu, S; Parajuli, KR; You, Z; Zhang, Q1
Burnet, M; Deuschle, U; Garnys, L; Hambruch, E; Hayden, H; Kremoser, C; Mitteregger, D; Oberhuber, G; Peck-Radosavljevic, M; Podesser, BK; Reiberger, T; Riedl, F; Rohr-Udilova, N; Schubert, TL; Schwabl, P; Seeland, BA; Starlinger, P; Strobel, B; Trauner, M; Wagner, M1
de Jong, JR; de Korte, MA; de Vries, EG; den Dunnen, WF; Garcia-Echeverria, C; Hollema, H; Jensen, MR; Lub-de Hooge, MN; Nagengast, WB; Oude Munnink, TH; Quadt, C; Schröder, CP; Timmer-Bosscha, H; van Dongen, GA1
Akoum, A; Al-Abed, Y; Bazin, S; Foster, W; Girard, K; Guillemette, J; Khoufache, K; Roy, MC; Verreault, JP1
Geissler, EK; Hackl, C; Lang, SA; Moser, C; Scheiffert, E; Schlitt, HJ; Stoeltzing, O; Wagner, C1
Barsoum, J; Borella, C; Foley, KP; Jiang, J; Korbut, T; Li, H; Sang, J; Sonderfan, AJ; Wu, Y; Ye, J; Zhang, M; Zhang, X; Zhou, D1
Fukazawa, T; Honami, T; Ibaragi, S; Mohammad Monsur Hassan, N; Naomoto, Y; Okui, T; Sasaki, A; Shimo, T; Takaoka, M1
Mall, JW; Myers, JA; Philipp, AW; Pollmann, C; Saclarides, TJ; Xu, X1
Amano, H; Hayashi, I; Inukai, M; Kamata, M; Kitasato, H; Majima, M; Yoshida, S; Yoshimura, H1
Maity, P; Roy, S1
Bichat, F; Fujiwara, Y; Guilbaud, N; Hasegawa, K; Isae, T; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Suzuki, R; Taguchi, E; Takahashi, K; Yamamoto, A1
Isoe, T; Miura, T; Nakamura, K; Shibuya, M; Taguchi, E1
Aherne, W; Barril, X; Box, G; Boxall, F; Boxall, K; Brough, PA; Cansfield, JE; Cheung, KM; de Haven Brandon, A; Drysdale, MJ; Dymock, B; Eccles, SA; Finch, H; Gowan, S; Hayes, A; Howes, R; Hubbard, RE; James, K; Jones, K; Kalusa, A; Martins, V; Massey, A; Matthews, TP; McDonald, E; Patterson, L; Pearl, L; Prodromou, C; Raynaud, FI; Rowlands, M; Sharp, SY; Surgenor, A; Urban, F; Valenti, M; Webb, P; Wood, M; Workman, P; Wright, L1

Other Studies

17 other study(ies) available for isoxazoles and Angiogenesis, Pathologic

ArticleYear
Cyclooxygenase-2 promotes pulmonary intravascular macrophage accumulation by exacerbating BMP signaling in rat experimental hepatopulmonary syndrome.
    Biochemical pharmacology, 2017, 08-15, Volume: 138

    Topics: Animals; Bone Morphogenetic Protein 2; Carrier Proteins; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Endothelium, Vascular; Hepatopulmonary Syndrome; Injections, Intraperitoneal; Injections, Intravenous; Isoxazoles; Lung; Macrophage Activation; Macrophages, Alveolar; Microvessels; Neovascularization, Pathologic; Rats, Sprague-Dawley; Recombinant Proteins; Signal Transduction

2017
Synthesis and Screening of Pro-apoptotic and Angio-inhibitory Activity of Novel Benzisoxazole Derivatives both In Vitro and In Vivo.
    Anti-cancer agents in medicinal chemistry, 2019, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles; Mammary Neoplasms, Animal; Mice; Molecular Structure; Neovascularization, Pathologic; Rats; Structure-Activity Relationship

2019
Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
    European journal of pharmacology, 2014, Jan-15, Volume: 723

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Antirheumatic Agents; Carcinogens; Carcinoma, Hepatocellular; Curcumin; Diethylnitrosamine; Drug Therapy, Combination; Hypoxia-Inducible Factor 1, alpha Subunit; Isoxazoles; Leflunomide; Liver; Liver Neoplasms; Male; Mice; Neovascularization, Pathologic; Perindopril; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A

2014
Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
    Molecular medicine reports, 2015, Volume: 12, Issue:2

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Diffusion Chambers, Culture; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Hep G2 Cells; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Resorcinols; Signal Transduction

2015
Aminomethylphosphonic acid inhibits growth and metastasis of human prostate cancer in an orthotopic xenograft mouse model.
    Oncotarget, 2016, Mar-01, Volume: 7, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cyclin D1; Disease Models, Animal; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Organophosphonates; Prostatic Neoplasms; Tetrazoles; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays

2016
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Journal of hepatology, 2017, Volume: 66, Issue:4

    Topics: Animals; Benzoates; Bile Acids and Salts; Bilirubin; Capillaries; Cholesterol; Disease Models, Animal; Hypertension, Portal; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Vascular Remodeling; Vascular Resistance

2017
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Immunohistochemistry; Isoxazoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Resorcinols; Tissue Distribution; Vascular Endothelial Growth Factor A; Zirconium

2010
Macrophage migration inhibitory factor antagonist blocks the development of endometriosis in vivo.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Animals; Cell Adhesion; Cyclooxygenase 2; DNA Primers; Endometriosis; Female; Gene Expression Regulation; Histological Techniques; Humans; Integrin alphaV; Integrin beta3; Interleukin-8; Intramolecular Oxidoreductases; Isoxazoles; Macrophage Migration-Inhibitory Factors; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neovascularization, Pathologic; Real-Time Polymerase Chain Reaction; Statistics, Nonparametric; Vascular Endothelial Growth Factor A

2012
Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Animals; Cell Communication; Cell Growth Processes; Cell Line, Tumor; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neovascularization, Pathologic; Pancreatic Neoplasms; Random Allocation; Resorcinols; Signal Transduction; Xenograft Model Antitumor Assays

2012
The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 343, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Survival; Dogs; Female; Heart; Hemodynamics; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Microcirculation; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Rabbits; Regional Blood Flow; Tubulin Modulators; Xenograft Model Antitumor Assays

2012
Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Current cancer drug targets, 2013, Volume: 13, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cells, Cultured; Female; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Isoxazoles; Mice; Mice, Nude; Molecular Targeted Therapy; Mouth Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Protein Kinase Inhibitors; Random Allocation; Resorcinols; Sirolimus; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2013
[Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in the mouse model].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2002, Volume: 73, Issue:7

    Topics: Administration, Oral; Animals; Capillaries; Cell Division; Colonic Neoplasms; HT29 Cells; Humans; Injections, Intraperitoneal; Isoxazoles; Leflunomide; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Random Allocation; Uridine

2002
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.
    Laboratory investigation; a journal of technical methods and pathology, 2003, Volume: 83, Issue:10

    Topics: Animals; Antibodies, Blocking; Aspirin; Benzenesulfonates; Carcinoma, Lewis Lung; Cyclooxygenase Inhibitors; Disease Models, Animal; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Isoxazoles; Lymphokines; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Nitrobenzenes; Oxazoles; Prostaglandin-Endoperoxide Synthases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma 180; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
Effect of glutamine analogue-acivicin on tumor induced angiogenesis in Ehrlich ascites carcinoma.
    Indian journal of experimental biology, 2005, Volume: 43, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Ehrlich Tumor; Isoxazoles; Male; Mice; Neovascularization, Pathologic

2005
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Cancer research, 2006, Sep-15, Volume: 66, Issue:18

    Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Endothelial Cells; Humans; Isoxazoles; Magnetic Resonance Imaging; Mice; Neoplasms; Neovascularization, Pathologic; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2006
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
    Cancer science, 2008, Volume: 99, Issue:3

    Topics: Animals; Antineoplastic Agents; Ascites; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Humans; Isoxazoles; Neovascularization, Pathologic; Peritoneal Neoplasms; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Receptors, Vascular Endothelial Growth Factor

2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
    Cancer research, 2008, Apr-15, Volume: 68, Issue:8

    Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Cycle; Cell Division; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Resorcinols; Transplantation, Heterologous

2008